Drug news
FDA accepts filing of Lodotra (Horizon Pharma) for Rheumatoid Arthritis
The FDA has accepted a new drug application for Lodotra, from Horizon Pharma, being a modified delayed-release formulation of low-dose prednisone, as a treatment for Rheumatoid Arthritis in adults. The FDA has established 26 July 2012 as the Prescription Drug User Fee Act action date. Lodotra is approved for marketing by Merck-Serono and MundiPharma in 16 European countries, for Rheumatoid Arthritis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins